Tag Archives: RE-NOVATE 2

Pradaxa is as Effective as Lovenox in Preventing VTE-event in Patients Setting Undergoing Hip Surgery: RE-NOVATE 2 study

Posted on June 26, 2010 by wngai

In a randomized trial that was reported at the 2010 Congress of the European Hematology Association (EHA), the oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) was found to be as effective as subcutaneous enoxaparin (Lovenox, Sanofi-Aventis) in preventing venous thromboembolism (VTE) … Continue reading →

Posted in Arrhythmia, Cardiovascular disease, Heart attack, Stroke, VTE | Tagged , , , , , , , , | 1 Comment